Warning Letter: Pragmatic Materials

News
Article

Warning Letter: Pragmatic Materials

On June 17, the Food and Drug Administration's Cincinnati officeissued a warningletter to Pragmatic Materials, Inc. (Solon, OH), a company thatrepackages active pharmaceutical ingredients (APIs) for sale topharmacies for compounding.

FDA said the company routinely listed manufacturers' expirationdates on the labels of repackaged products, even though itreplaced the manufacturers' original inert and airtight packages (oftenwith an inert gas overlay) with more porous packages... withoutperforming additional stability or container tests. The products citedwere NADH (nicotinamide-adenine dinucleotide, reduced sodiumsalt), oxytocin, streptomycin sulfate USP, polymyxin Bsulfate, gentamycin sulfate,  and cromolyn sodium.

The agency also criticized Pragmatic Materials for repackagingtechnical grade EDTA Disodium as USP grade for prescriptioncompounding—without performing the additional tests necessary tosupport the higher grade rating.

In its letter, the agency acknowledged the company'scounterarguments and efforts at remediation, but said they fell short.



Recent Videos
Miguel Forte from ISCT and Kiji Therapeutics provides his insights into the changing political landscape in the US as well as legislative and regulatory adjustments
Miguel Forte from ISCT and Kiji Therapeutics chats about expectations for 2025 and the future technology agenda for industry.
Mike Baird from Schlafender Hase gives his predictions for how AI and ML may find use in the industry moving forwards and provides some predictions about M&A and the changing US government administration.
Preeya Beczek from Beczek.COM gives her thoughts on the areas to watch with the new US administration and how Europe might be finalizing preparations for previous legislative changes
Drug Digest: Challenges and Triumphs in Next-Generation Biotherapeutic Development
Related Content